Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for lestaurtinib (compound)
Most Correlated Studies
- Prostate adenocarcinoma LNCaP cells with PKN1 inhibition treated with R1881
- Human erythroleukemia cells treated with CEP701 or PRMT5-knockdown
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
Most Relevant Literature
- Lestaurtinib (CEP-701) reduces the duration of limbic status epilepticus in periadolescent rats.
- Ponatinib, Lestaurtinib, and mTOR/PI3K Inhibitors Are Promising Repurposing Candidates against Entam…
- FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymp…
- Lestaurtinib potentiates TRAIL-induced apoptosis in glioma via CHOP-dependent DR5 induction.
- Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models.
Most Relevant Clinical Trials
- CEP-701 (Lestaurtinib) in Myelofibrosis
- Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Ac…
- Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thro…
- Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagno…
- Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia
